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Vaccination Practice for Pediatric Inflammatory Disease Patients Receiving
Immuno-suppressive Therapy
Naser Tolaymat MD, FACG; Clare M. Lenhart, PhD, MPH

Children’s Hospital at Lehigh Valley Health Network, Allentown, PA

Purpose:

• 83% of responders reported having patients on IS.

Table 2. Vaccines considered safe in Pediatric IBD patient receiving IS therapy

• Most respondents (53%, N=32) have treated pediatric patients on IS
therapy;

The number of pediatric inflammatory bowel disease (IBD)
patients receiving long-term Immuno-suppressive therapy (IS)
has increased in the past several years. The administration
of live attenuated vaccines (LAV) should be avoided in these
1
patients. Our needs assessment survey examined current
vaccination practices and related knowledge of primary care
physicians regarding vaccination of IBD patients receiving IS
therapy.

• Thirty-nine percent of responders (N=23) review vaccination history
at every visit.
• Nearly all providers identified non-live attenuated vaccines as
safe (94%-100% depending on vaccine type) and recommend
administration to IS patients.
• However, survey responses identified challenges in provider
knowledge and perception of safety surrounding life attenuated
vaccines.

Method:
Online close-ended, 13-item questionnaires were sent to
primary care physicians including residents and attendings from
pediatrics and family practice at the local institution. Descriptive
statistics are reported and comparisons of responses between
pediatric and family medicine providers were made using chisquare.

• Providers have recommended live attenuated vaccines to IS
pediatric patients. Intranasal Flu 5% (N=3), varicella 12% (N=7) and
MMR 17% (N=10).
• Intranasal influenza was considered a safe vaccine by 18% of
respondents (N=11), varicella by 17% (N=10) and MMR by 32%
(N=19).

• Sixty primary care
physicians completed
questionnaires.
• Responses represented
residents (30%, N=18) and
practicing physicians (70%,
N=42) and encompassed
both pediatric (43%, N=26)
and family medicine (57%,
N=34) specialties.
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P-value

Varicella

24%

8%

0.2

MMR

41%

19%

0.126

Conclusion:
There is significant misconception among primary care
physicians regarding safe vaccination practices for pediatric
patients receiving IS therapy. More education is necessary for
pediatric and family medicine providers to improve physician
knowledge and ensure safe immunization administration for
pediatric IBD patients receiving long-term Immuno-suppressive
therapy.
Desired Sources of Additional Information on Vaccine Safety
Percent

N

Printed document in the office

61.70%

37

Flyer on office wall

16.70%

10

Grand Rounds presentation

21.70%

13

Intranet reference

56.70%

34

Reference within EMR/powerchart

18.30%

11

AAP’s Red Book

11.70%

7

Other

6.70%

4

Source

Table 1. Vaccination Pediatric IBD patient receiving IS therapy
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Pediatricians

• Further, fewer family medicine providers (35%, N=12) than
pediatricians (69%, N=18) correctly identified all three live attenuated
vaccines as unsafe to administer to IS patients (p=0.019).

Results:
Study Participants

Family Physicians

Reference:

• A greater proportion of family medicine physicians considered
varicella and MMR vaccines safe to administer to IS patients than
did pediatricians (varicella, 24% versus 8%, p=0.2; MMR, 41%
versus 19%, P=0.126).
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